Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 26.26 -0.04% -0.01
ZNTL closed up 2.06 percent on Friday, June 2, 2023, on 1.27 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish -0.04%
Golden Cross Bullish -0.04%
Calm After Storm Range Contraction -0.04%
NR7 Range Contraction -0.04%
NR7-2 Range Contraction -0.04%
Narrow Range Bar Range Contraction -0.04%
Fell Below 20 DMA Bearish 2.02%
Calm After Storm Range Contraction 2.02%
NR7 Range Contraction 2.02%
NR7-2 Range Contraction 2.02%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 4 hours ago
20 DMA Support about 4 hours ago
Rose Above Previous Day's High about 4 hours ago
20 DMA Resistance about 4 hours ago
Down 2 % about 4 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Molecule Therapeutics Estrogen Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors

Is ZNTL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.24
52 Week Low 15.57
Average Volume 863,788
200-Day Moving Average 21.97
50-Day Moving Average 21.98
20-Day Moving Average 26.10
10-Day Moving Average 26.87
Average True Range 1.78
RSI (14) 55.56
ADX 41.62
+DI 27.65
-DI 10.17
Chandelier Exit (Long, 3 ATRs) 26.13
Chandelier Exit (Short, 3 ATRs) 26.24
Upper Bollinger Bands 29.92
Lower Bollinger Band 22.29
Percent B (%b) 0.52
BandWidth 29.23
MACD Line 1.31
MACD Signal Line 1.63
MACD Histogram -0.3223
Fundamentals Value
Market Cap 1.07 Billion
Num Shares 40.6 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 6.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.43
Resistance 3 (R3) 27.34 26.86 27.24
Resistance 2 (R2) 26.86 26.57 26.91 27.17
Resistance 1 (R1) 26.57 26.38 26.72 26.66 27.11
Pivot Point 26.09 26.09 26.16 26.13 26.09
Support 1 (S1) 25.79 25.79 25.94 25.88 25.43
Support 2 (S2) 25.31 25.61 25.36 25.37
Support 3 (S3) 25.02 25.31 25.30
Support 4 (S4) 25.11